Comparative Pharmacology
Head-to-head clinical analysis: BREXAFEMME versus ETHINYL ESTRADIOL AND LEVONORGESTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREXAFEMME versus ETHINYL ESTRADIOL AND LEVONORGESTREL.
BREXAFEMME vs ETHINYL ESTRADIOL AND LEVONORGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREXAFEMME (ibrexafungerp) inhibits glucan synthase, an enzyme involved in fungal cell wall synthesis, disrupting cell wall integrity and causing fungal cell death.
Combination hormonal contraceptive; ethinyl estradiol provides estrogenic activity, levonorgestrel provides progestational activity, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
200 mg orally once daily.
One tablet containing 0.02-0.05 mg ethinyl estradiol and 0.1-0.15 mg levonorgestrel orally once daily for 21 days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
The terminal elimination half-life of ibrexafungerp is approximately 20-30 hours in healthy subjects, supporting once-daily oral dosing without need for a loading dose.
Ethinyl estradiol: 13-27 hours (terminal). Levonorgestrel: 18-30 hours (terminal). Clinical context: steady state achieved in 5-7 days; missed doses may require backup contraception.
Ibrexafungerp is primarily eliminated via the biliary/fecal route. In clinical studies, approximately 51% of the dose was recovered in feces (as unchanged drug and metabolites) and ~1% in urine. Renal excretion is negligible.
Urine (40% ethinyl estradiol metabolites, 40% levonorgestrel metabolites); feces (40% ethinyl estradiol, 20% levonorgestrel).
Category C
Category D/X
Estrogen
Estrogen